Philips’ DEFINE GPS Trial Will Assess Outcomes of PCI Guided by an Integrated Platform of iFR and Angiogram
February 11, 2020—Royal Philips announced a new randomized controlled trial to assess patient outcomes after receiving percutaneous coronary intervention (PCI) guided by Philips’ coregistration platform (which combines data of instant wave-free ratio (iFR) measurement and angiography) compared with the standard of care treatment guided by angiography alone.
Medtronic Begins SPYRAL DYSTAL Pilot Study of Renal Denervation in Hypertensive Patients
February 4, 2020—Medtronic announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity Spyral renal denervation (RDN) system using a targeted procedural approach with a reduced number of radiofrequency (RF) ablations.
Study From CathPCI Registry Analyzes Trends in Usage and Outcomes of Coronary Atherectomy
January 24, 2020—Nirat Beohar, MD, et al conducted a study that sought to assess the trends in usage, interhospital variability, and outcomes with coronary atherectomy (CA) among patients undergoing percutaneous coronary intervention (PCI).
Three-Year Findings Published for Mortality of Repeat Revascularizations in the EXCEL Trial
January 15, 2020—The 3-year findings from an investigation to determine the incidence and impact on mortality of repeat revascularization after index percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) in the EXCEL trial were published by Gennaro Giustino, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
Study Confirms Prognostic Value of the GRACE Discharge Score for PCI in Stable CAD Patients
January 10, 2020—Xue Yan Zhao, MD, published findings from a study to assess the predictive value of the Global Registry of Acute Coronary Events (GRACE) discharge score for patients with stable coronary artery disease (CAD) after percutaneous coronary intervention (PCI).
Proximo Medical Named Commercialization Partner for CeloNova BioSciences in Select United States Markets
January 8, 2020—Proximo Medical, LLC, announced a partnership in select United States markets with CeloNova Biosciences, Inc. Proximo Medical is a fractional commercial organization for start-up medical device technologies and established medical device companies looking to expand adoption in the United States.
EACTS Seeks to Collaborate With EXCEL Investigators to Resolve Trial Data Concerns
January 7, 2020—The European Association for Cardio-Thoracic Surgery (EACTS) announced that its Secretary General, Professor Domenico Pagano, MD, on behalf of the EACTS Council, has written to the principal investigators of the EXCEL trial to offer assistance to resolve concerns that have been raised about the trial.
SCAI Publishes Updated Best Practices for Transradial Angiography and Interventions
December 27, 2019—The Society of Cardiovascular Angiography and Interventions (SCAI) published their expert consensus statement update on best practices for transradial angiography and intervention online ahead of print in Catheterization & Cardiovascular Interventions.
EXCEL Investigators Issue Detailed Response to BBC and EACTS Claims on Trial Conduct and Data Interpretation
December 12, 2019—Gregg W. Stone, MD, et al on behalf of the EXCEL leadership issued a response to the recent news reports and society statements questioning the conduct and data of the EXCEL trial.
Medicure Completes Enrollment in FABOLUS-FASTER Trial of Aggrastat in Patients Undergoing PCI
December 12, 2019—Medicure Inc. announced the completion of the FABOLUS-FASTER phase 4 trial of Aggrastat (tirofiban hydrochloride) injection versus Kengreal (cangrelor; The Medicines Company) in patients undergoing percutaneous coronary intervention (PCI).
EACTS Withdraws Support of Left Main Chapter of European Guidelines for Myocardial Revascularization After BBC Investigation of the EXCEL Trial
December 9, 2019—Professor Domenico Pagano, MD, Secretary General of the European Association for Cardiothoracic Surgery (EACTS), issued a statement in response to the report of the United Kingdom’s BBC Newsnight investigation on the EXCEL trial and the society’s subsequent withdrawal of support for the current guidelines related to myocardial revascularization for left main coronary artery disease (LMCAD) that were established jointly by EACTS and the European Society of Cardiology (ESC).
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.